Ertugliflozin for Functional Mitral Regurgitation

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 128 participants.

Also called NCT04231331

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 128 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04231331
Other papers using this trial's data
  • Ertugliflozin for Functional Mitral Regurgitation Associated With Heart Failure: EFFORT Trial Circulation, 2024-06-11 DOI, PubMed 38690659

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04231331. Randomized; quadruple masking; primary purpose treatment. Start 2020-11-04 (actual); primary completion 2023-11-15 (actual). Results posted on 2025-01-06.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Ertugliflozin for Functional Mitral Regurgitation
Acronym
EFFORT
Condition
Mitral Valve Insufficiency
Condition
Left Ventricular Systolic Dysfunction
Intervention (Drug)
Ertugliflozin
Intervention (Drug)
Placebo
Lead sponsor
Asan Medical Center (class: other)
Collaborator
Merck Sharp & Dohme LLC (class: industry)

Record details

Record id
cardio:ct-nct04231331
Content hash
de009f5cdeefb5e4f3343400be1e3eeb8952ce1c2477ff9895087bc638116b94